Figure 6.

Comparison of Therapeutic Effects between Intra-Amniotic CRMP4 siRNA + BMSC Injection and Intra-Spinal CRMP4 siRNA + BMSC Injection for Spina Bifida

(A) Relative mRNA expression of Crmp4 in the spinal cord of fetuses of E21 spina bifida with CRMP4 siRNA + BMSC treatment through intra-amniotic (n = 9) and intra-spinal (n = 9) injection. (B) Quantitative analysis of the skin lesion area comparing the intra-amniotic CRMP4 siRNA + BMSC-injected fetuses (n = 25) and intra-spinal CRMP4 siRNA + BMSC-injected groups (n = 27). (C) Relative mRNA expression of Casepase3, Casepase9, and Bcl2 and Bax in the spinal cord of E21 rat fetuses in the intra-amniotic CRMP4 siRNA + BMSC injection group (n = 9) and intra-spinal CRMP4 siRNA + BMSC injection group (n = 9). (D) Relative mRNA expression of Nf, Map2, Tau, Synaptotagmin, Synapsin1, Tubulin, Hb9, and Brn3a in the spinal cord of E21 rat fetuses in the intra-amniotic CRMP4 siRNA + BMSC injection group (n = 9) and intra-spinal CRMP4 siRNA + BMSC injection group (n = 9). (E) Relative mRNA expression of Ngf, Egf, Igf, Fgf2, Fgf10, Bdnf, Tgf-beta, and Vegf in the spinal cord of E21 rat fetuses in the intra-amniotic CRMP4 siRNA + BMSC injection group (n = 9) and intra-spinal CRMP4 siRNA + BMSC injection group (n = 9). Values present fold expression differences compared with the intra-amniotic CRMP4 siRNA + BMSC injection group. Data are presented as the mean ± SEM. Statistical significance according to a Student’s t test is indicated. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.490537517525990049053751752599004905375175259900